Pancreatic Cancer Research

ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Mariano Ponz‐Sarvisé

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3240-729X; OpenAlex author ID A5028783464. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 22

  1. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  2. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 St… Co-author DOI 10.1158/2767-9764.crc-26-0018↗
  3. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. Last author DOI 10.1002/cpt.3528↗
  4. Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology. Co-author DOI 10.1038/s12276-024-01378-w↗
  5. Quantitative evaluation of the role of the microenvironment in the phenotype, metabolism, and drug resistance of PDAC tumor organoids Co-author DOI 10.1101/2024.12.31.630904↗
  6. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03268-5↗
  7. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  8. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials. Co-author DOI 10.1093/bjsopen/zrae087↗
  9. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  10. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.03.001↗
  11. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Co-author DOI 10.1158/1078-0432.ccr-22-0794↗
  12. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  13. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? Last author DOI 10.3389/fcell.2021.787249↗
  14. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  15. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  16. Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack. Last author DOI 10.1158/1078-0432.ccr-19-1753↗
  17. Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. Co-author DOI 10.3390/cancers11050606↗
  18. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Co-author DOI 10.1038/ncomms14294↗
  19. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  20. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  21. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  22. Mouse Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2015.04.010↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Silvestre Vicent Cambra · 5 shared papers, 2017–2025 · strength 0.83
  2. Teresa Mercade Macarulla · 5 shared papers, 2020–2026 · strength 0.74
  3. Daniel Öhlund · 6 shared papers, 2015–2025 · strength 0.62
  4. Shruthi Narayanan · 3 shared papers, 2021–2025 · strength 0.61
  5. Vincenzo Corbo · 5 shared papers, 2015–2025 · strength 0.58
  6. Do‐Youn Oh · 2 shared papers, 2025–2026 · strength 0.46
  7. Fernando Rotellar Sastre · 3 shared papers, 2019–2024 · strength 0.45
  8. Tobiloba E. Oni · 4 shared papers, 2015–2025 · strength 0.44
  9. Chang‐Il Hwang · 4 shared papers, 2015–2025 · strength 0.44
  10. Jens Thomas Siveke · 2 shared papers, 2023–2026 · strength 0.38
  11. Angela Tatiana Alistar · 2 shared papers, 2021–2026 · strength 0.34
  12. Manuel M. Hidalgo · 3 shared papers, 2020–2025 · strength 0.34
  13. Jaime Feliú · 3 shared papers, 2020–2025 · strength 0.34
  14. Bruno Bockorny · 3 shared papers, 2020–2025 · strength 0.34
  15. Christos K Fountzilas · 2 shared papers, 2024–2025 · strength 0.32
  16. Javier Rodríguez Rodríguez · 2 shared papers, 2019–2024 · strength 0.29
  17. Jihao Xu · 1 shared paper, 2025 · strength 0.28
  18. David Arthur Tuveson · 5 shared papers, 2015–2019 · strength 0.28
  19. Kenneth H. Yu · 4 shared papers, 2015–2019 · strength 0.27
  20. Ioritz Sorzabal-Bellido · 1 shared paper, 2025 · strength 0.25
  21. Carlos Ortíz-de-Solórzano · 1 shared paper, 2025 · strength 0.25
  22. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.24
  23. Ben George · 1 shared paper, 2026 · strength 0.24
  24. Vincent M. Chung · 1 shared paper, 2026 · strength 0.24
  25. Jill Lacy · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.